These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8591802)

  • 1. Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea.
    Piolti R; Appollonio I; Perego M; Pozzi C; Rovati L; Ferrarese C; Frattola L
    Eur Neurol; 1995; 35(6):344-8. PubMed ID: 8591802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
    Innis RB; Bunney BS; Charney DS; Price LH; Glazer WM; Sternberg DE; Rubin AL; Heninger GR
    Psychiatry Res; 1986 May; 18(1):1-7. PubMed ID: 3737785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease.
    Girotti F; Carella F; Scigliano G; Grassi MP; Soliveri P; Giovannini P; Parati E; Caraceni T
    J Neurol Neurosurg Psychiatry; 1984 Aug; 47(8):848-52. PubMed ID: 6147393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
    van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of latent inhibition in the rat by the CCK antagonist proglumide.
    Gracey DJ; Bell R; King DJ; Trimble KM; McDermott BJ
    Pharmacol Biochem Behav; 1998 Apr; 59(4):1053-9. PubMed ID: 9586867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea.
    Leonard DP; Kidson MA; Brown JG; Shannon PJ; Taryan S
    Aust N Z J Psychiatry; 1975 Jun; 9(2):115-8. PubMed ID: 125578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study.
    Cann PA; Rovati LC; Smart HL; Spiller RC; Whorwell PJ
    Ann N Y Acad Sci; 1994 Mar; 713():449-50. PubMed ID: 8185213
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical evaluation of amantadine and haloperidol in Huntington's chorea.
    Saran BM; Klein MS; Benay EM
    J Clin Psychiatry; 1980 Jun; 41(6):221. PubMed ID: 6445900
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of chorea (author's transl)].
    Murai Y; Yoshida M; Yanagisawa N
    Rinsho Shinkeigaku; 1977 Dec; 17(12):811-5. PubMed ID: 24511
    [No Abstract]   [Full Text] [Related]  

  • 11. Proglumide as a morphine adjunct in cancer pain management.
    Bernstein ZP; Yucht S; Battista E; Lema M; Spaulding MB
    J Pain Symptom Manage; 1998 May; 15(5):314-20. PubMed ID: 9654837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements].
    Giménez-Roldán S; Mateo D
    Neurologia; 1989 Oct; 4(8):282-7. PubMed ID: 2534679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proglumide, a cholecystokinin receptor antagonist, exacerbates beta, beta'-iminodipropionitrile-induced dyskinetic syndrome in rats.
    Tariq M; Khan HA; Rehana Z; Al Moutaery K; Al Deeb S
    Neurotoxicol Teratol; 1998; 20(5):571-9. PubMed ID: 9761597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet dopamine uptake in Huntington's chorea and Gilles de la Tourette's syndrome: effect of haloperidol.
    Butterworth RF; Gonce M; Barbeau A
    Can J Neurol Sci; 1977 Nov; 4(4):285-8. PubMed ID: 145893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma homovanillic acid and prolactin in Huntington's disease.
    Markianos M; Panas M; Kalfakis N; Vassilopoulos D
    Neurochem Res; 2009 May; 34(5):917-22. PubMed ID: 18841471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum haloperidol concentration and choreiform movements in Huntington's disease.
    Barr AN; Fischer JH; Koller WC; Spunt AL; Singhal A
    Neurology; 1988 Jan; 38(1):84-8. PubMed ID: 2962009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain.
    McCleane GJ
    Anesth Analg; 1998 Nov; 87(5):1117-20. PubMed ID: 9806692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gait abnormality of Huntington's disease.
    Koller WC; Trimble J
    Neurology; 1985 Oct; 35(10):1450-4. PubMed ID: 3162109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of Huntington's chorea. Personal experience.
    Caraceni T; Giovannini P; Girotti F; Avanzini G
    Eur Neurol; 1977; 16(1-6):42-50. PubMed ID: 150332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.